REGULATORY

Chuikyo OKs Listing of Tevimbra, Camzyos, Tremfya, and More

May 15, 2025

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The Central Social Insurance Medical Council (Chuikyo) gave its blessing to the NHI price listing of 10 medicines/APIs at its general meeting on May 14, with BeiGene’s PD-1 inhibitor Tevimbra (tislelizumab) carrying the biggest peak sales outlook among them. The…

To read the full story

BeiGene Japan Rebrands as BeOne, Debuts PD-1 Inhibitor Tevimbra
July 2, 2025
Takeda’s Livmarli, HyQvia Now Available in Japan
June 13, 2025
Servier Launches Tibsovo for IDH1-Mutated AML in Japan
June 3, 2025
Camzyos, Tremfya, Tivdak, and More Now Available in Japan
May 22, 2025
Japan Approves J&J’s Lazcluze, Genmab’s Tivdak, and More
March 28, 2025

REGULATORY

MHLW Pharma Director Says Uniform Drug Price Hike “Not Realistic,” Targeted Support Preferred
January 9, 2026
MHLW Issues Guidance on Revised PMD Act Ahead of May Enforcement
January 6, 2026
MHLW Sets Up Drug Discovery Support Office Ahead of New Fund Launch
January 6, 2026
Ex-JPMA President Ueno Takes on New AMED Advisor Role
January 6, 2026
Cabinet OKs FY2026 Tax Reform Package, Creates Strategic Tech R&D Credit
January 5, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Gist of FY2026 Drug Pricing Reform Outline

The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…

COMMENTARY

Wave of “World Firsts” Looms as 47 New Drug Candidates Line Up for 2026

By Shinya Sato

As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…

COLUMN

AI: Your New HR BFF (Not Your Replacement!)

By Philip Carrigan

Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…